Combined immunotherapy of colorectal cancer in young patient with microsatellite instability (clinical case)
- 28 June 2021
- journal article
- research article
- Published by Alfmed LLC in Medical alphabet
- No. 10,p. 16-21
Abstract
Комбинированная иммунотерапия колоректального рака у молодой пациентки с микросаттелитной нестабильностью (клинический случай)Keywords
This publication has 21 references indexed in Scilit:
- Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal CancersJCO Precision Oncology, 2018
- CELLULAR IMMUNOTHERAPY: A MODERN APPROACH TO TREATMENT OF ONCOLOGICAL DISEASESMedical Immunology (Russia), 2018
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).Journal of Clinical Oncology, 2018
- Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal CancerArchives of Pathology & Laboratory Medicine, 2017
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancersAnnals of Oncology, 2017
- A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instabilityAnnals of Oncology, 2017
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyThe Lancet Oncology, 2017
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In VivoThe Journal of Immunology, 2015